SCHEMBL3976138

SCHEMBL3976138

COc1ccc(C(=O)NNC(=O)c2occ(-c3ccccc3)c2-c2ccccc2)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.50
LMNA P02545 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HTT P42858 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982880 0.84 KMT2A (0.54) RAB9ALMNANPSR1MAPTSMN1; SMN2
SCHEMBL3978634 0.81 CYP3A4 (0.56) RAB9ALMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL3974631 0.81 CTSA (0.47) LMNAMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL3977741 0.79 GCGR (0.49) RAB9ALMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL3982336 0.78 LMNA (0.47) RAB9ALMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL3976996 0.78 L3MBTL1 (0.51) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL3974199 0.78 ALDH1A1 (0.59) RAB9ALMNANPSR1MAPTSMN1; SMN2
SCHEMBL3978024 0.78 CYP3A4 (0.45) RAB9ALMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL3982902 0.77 CA1 (0.46) RAB9ALMNANPSR1MAPTSMN1; SMN2
SCHEMBL3977652 0.77 MEN1 (0.60) RAB9ALMNANPSR1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 RAB9A 2501/4885LMNA 2180/4885NPSR1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.